nrf2 inhibitor ml385 Search Results


ml385  (MedChemExpress)
96
MedChemExpress ml385
Ml385, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ml385/product/MedChemExpress
Average 96 stars, based on 1 article reviews
ml385 - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
ml385  (Axon Medchem LLC)
90
Axon Medchem LLC ml385
Nrf2 is a negative regulator of STING during metabolic reprogramming. a Lactate and glucose were measured in supernatants from PMDC05 cells stimulated with LPS (1 μg mL −1 ) or gardiquimod (4 µg ml −1 ) for 24 h. Data are the means and s.e.m. from one of two independent experiments performed in septuplicates. b , c Itaconate was measured in the cell medium and in the cell pellets of LPS-stimulated PMDC05 by LC/MS. Data are the means and s.e.m. from one of two independent. d PMDC05 stimulated with LPS (200 ng mL −1 ) or gardiquimod (400 ng ml −1 ) for 24 h were lysed and analysed for HIF1α, IFIT1, and Vinculin (VCL) as loading control. e PMDC05 cells were stimulated with gardiquimod (4 μg mL −1 ), LPS (1 μg mL −1 ), CpG (4 μg mL −1 ), cGAMP (4 μg mL −1 ), or Poly (I:C) (4 μg mL −1 ) for 24, 48, or 72 h. Whole-cell extracts were analysed by immunoblotting. f TMEM173 mRNA was assessed by qPCR in PMDC05 stimulated with indicated agonists for 48 h. Data are the means ± s.e.m. of one experiment performed in triplicate. g PMDC05 cells were pre-treated with the Nrf2 inhibitor <t>ML385</t> (20 µM) before stimulation with LPS (1 μg mL −1 ) or gardiquimod (4 μg mL −1 ) for 72 h. Cells were then lysed and lysates were analysed by western blotting. h PMDC05 cells were pre-stimulated with gardiquimod (4 μg mL −1 ) or LPS (1 μg mL −1 ) for 72 h before challenge with cGAMP (4 μg mL −1 ) for 24 h. Type I IFN release was assessed using a HEK-Blue assay. Data are the means ± s.e.m. of one representative experiment performed in triplicate. i Graphical display of how 4-OI might possibly activate Nrf2. j HEK293T cells were treated with increasing doses of 4-OI (30–250 μM) for 18 h. ARE-promoter activity was assessed by luciferase assay. Data are means ± s.e.m. of two independent experiments in triplicate. k THP1 cells were treated with SFN (20 μM) or 4-OI (125 μM) for 48 h and mRNA levels were determined by qPCR. l THP1 cells were pre-treated with increasing does of 4-OI (62.5–125 μM) for 72 h and challenged with cGAMP (4 μg mL −1 ). Whole-cell lysates were then blotted as indicated. Data are from one representative experiment that has been repeated twice. m – n THP1 cells were pre-treated with 4-OI (125 μM) for 72 h before challenge of 24 h with cGAMP (4 μg mL −1 ). Supernatants were assessed for type I IFN by HEK-Blue cell assay ( m ) and whole-cell lysates by immunoblotting ( n ). o , p HaCat and A549 cells were treated with Nrf2 siRNA for 72 h and for 48 h, respectively, before treatment with 4-OI (125 μM) for 48 h. Whole-cell lysates were used for immunoblotting. q – s mRNA levels ( q , r ) and protein levels ( s ) were assessed by qPCR and immunoblotting in hMDMs silenced for Nrf2 by siRNA. Data are from two donors. Unpaired two-tailed Student’s t -test was used to determine significance
Ml385, supplied by Axon Medchem LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ml385/product/Axon Medchem LLC
Average 90 stars, based on 1 article reviews
ml385 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
nrf2 inhibitors ml385  (Baiao Pharmaceuticals)
90
Baiao Pharmaceuticals nrf2 inhibitors ml385
Nrf2 is a negative regulator of STING during metabolic reprogramming. a Lactate and glucose were measured in supernatants from PMDC05 cells stimulated with LPS (1 μg mL −1 ) or gardiquimod (4 µg ml −1 ) for 24 h. Data are the means and s.e.m. from one of two independent experiments performed in septuplicates. b , c Itaconate was measured in the cell medium and in the cell pellets of LPS-stimulated PMDC05 by LC/MS. Data are the means and s.e.m. from one of two independent. d PMDC05 stimulated with LPS (200 ng mL −1 ) or gardiquimod (400 ng ml −1 ) for 24 h were lysed and analysed for HIF1α, IFIT1, and Vinculin (VCL) as loading control. e PMDC05 cells were stimulated with gardiquimod (4 μg mL −1 ), LPS (1 μg mL −1 ), CpG (4 μg mL −1 ), cGAMP (4 μg mL −1 ), or Poly (I:C) (4 μg mL −1 ) for 24, 48, or 72 h. Whole-cell extracts were analysed by immunoblotting. f TMEM173 mRNA was assessed by qPCR in PMDC05 stimulated with indicated agonists for 48 h. Data are the means ± s.e.m. of one experiment performed in triplicate. g PMDC05 cells were pre-treated with the Nrf2 inhibitor <t>ML385</t> (20 µM) before stimulation with LPS (1 μg mL −1 ) or gardiquimod (4 μg mL −1 ) for 72 h. Cells were then lysed and lysates were analysed by western blotting. h PMDC05 cells were pre-stimulated with gardiquimod (4 μg mL −1 ) or LPS (1 μg mL −1 ) for 72 h before challenge with cGAMP (4 μg mL −1 ) for 24 h. Type I IFN release was assessed using a HEK-Blue assay. Data are the means ± s.e.m. of one representative experiment performed in triplicate. i Graphical display of how 4-OI might possibly activate Nrf2. j HEK293T cells were treated with increasing doses of 4-OI (30–250 μM) for 18 h. ARE-promoter activity was assessed by luciferase assay. Data are means ± s.e.m. of two independent experiments in triplicate. k THP1 cells were treated with SFN (20 μM) or 4-OI (125 μM) for 48 h and mRNA levels were determined by qPCR. l THP1 cells were pre-treated with increasing does of 4-OI (62.5–125 μM) for 72 h and challenged with cGAMP (4 μg mL −1 ). Whole-cell lysates were then blotted as indicated. Data are from one representative experiment that has been repeated twice. m – n THP1 cells were pre-treated with 4-OI (125 μM) for 72 h before challenge of 24 h with cGAMP (4 μg mL −1 ). Supernatants were assessed for type I IFN by HEK-Blue cell assay ( m ) and whole-cell lysates by immunoblotting ( n ). o , p HaCat and A549 cells were treated with Nrf2 siRNA for 72 h and for 48 h, respectively, before treatment with 4-OI (125 μM) for 48 h. Whole-cell lysates were used for immunoblotting. q – s mRNA levels ( q , r ) and protein levels ( s ) were assessed by qPCR and immunoblotting in hMDMs silenced for Nrf2 by siRNA. Data are from two donors. Unpaired two-tailed Student’s t -test was used to determine significance
Nrf2 Inhibitors Ml385, supplied by Baiao Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nrf2 inhibitors ml385/product/Baiao Pharmaceuticals
Average 90 stars, based on 1 article reviews
nrf2 inhibitors ml385 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Nrf2 is a negative regulator of STING during metabolic reprogramming. a Lactate and glucose were measured in supernatants from PMDC05 cells stimulated with LPS (1 μg mL −1 ) or gardiquimod (4 µg ml −1 ) for 24 h. Data are the means and s.e.m. from one of two independent experiments performed in septuplicates. b , c Itaconate was measured in the cell medium and in the cell pellets of LPS-stimulated PMDC05 by LC/MS. Data are the means and s.e.m. from one of two independent. d PMDC05 stimulated with LPS (200 ng mL −1 ) or gardiquimod (400 ng ml −1 ) for 24 h were lysed and analysed for HIF1α, IFIT1, and Vinculin (VCL) as loading control. e PMDC05 cells were stimulated with gardiquimod (4 μg mL −1 ), LPS (1 μg mL −1 ), CpG (4 μg mL −1 ), cGAMP (4 μg mL −1 ), or Poly (I:C) (4 μg mL −1 ) for 24, 48, or 72 h. Whole-cell extracts were analysed by immunoblotting. f TMEM173 mRNA was assessed by qPCR in PMDC05 stimulated with indicated agonists for 48 h. Data are the means ± s.e.m. of one experiment performed in triplicate. g PMDC05 cells were pre-treated with the Nrf2 inhibitor ML385 (20 µM) before stimulation with LPS (1 μg mL −1 ) or gardiquimod (4 μg mL −1 ) for 72 h. Cells were then lysed and lysates were analysed by western blotting. h PMDC05 cells were pre-stimulated with gardiquimod (4 μg mL −1 ) or LPS (1 μg mL −1 ) for 72 h before challenge with cGAMP (4 μg mL −1 ) for 24 h. Type I IFN release was assessed using a HEK-Blue assay. Data are the means ± s.e.m. of one representative experiment performed in triplicate. i Graphical display of how 4-OI might possibly activate Nrf2. j HEK293T cells were treated with increasing doses of 4-OI (30–250 μM) for 18 h. ARE-promoter activity was assessed by luciferase assay. Data are means ± s.e.m. of two independent experiments in triplicate. k THP1 cells were treated with SFN (20 μM) or 4-OI (125 μM) for 48 h and mRNA levels were determined by qPCR. l THP1 cells were pre-treated with increasing does of 4-OI (62.5–125 μM) for 72 h and challenged with cGAMP (4 μg mL −1 ). Whole-cell lysates were then blotted as indicated. Data are from one representative experiment that has been repeated twice. m – n THP1 cells were pre-treated with 4-OI (125 μM) for 72 h before challenge of 24 h with cGAMP (4 μg mL −1 ). Supernatants were assessed for type I IFN by HEK-Blue cell assay ( m ) and whole-cell lysates by immunoblotting ( n ). o , p HaCat and A549 cells were treated with Nrf2 siRNA for 72 h and for 48 h, respectively, before treatment with 4-OI (125 μM) for 48 h. Whole-cell lysates were used for immunoblotting. q – s mRNA levels ( q , r ) and protein levels ( s ) were assessed by qPCR and immunoblotting in hMDMs silenced for Nrf2 by siRNA. Data are from two donors. Unpaired two-tailed Student’s t -test was used to determine significance

Journal: Nature Communications

Article Title: Nrf2 negatively regulates STING indicating a link between antiviral sensing and metabolic reprogramming

doi: 10.1038/s41467-018-05861-7

Figure Lengend Snippet: Nrf2 is a negative regulator of STING during metabolic reprogramming. a Lactate and glucose were measured in supernatants from PMDC05 cells stimulated with LPS (1 μg mL −1 ) or gardiquimod (4 µg ml −1 ) for 24 h. Data are the means and s.e.m. from one of two independent experiments performed in septuplicates. b , c Itaconate was measured in the cell medium and in the cell pellets of LPS-stimulated PMDC05 by LC/MS. Data are the means and s.e.m. from one of two independent. d PMDC05 stimulated with LPS (200 ng mL −1 ) or gardiquimod (400 ng ml −1 ) for 24 h were lysed and analysed for HIF1α, IFIT1, and Vinculin (VCL) as loading control. e PMDC05 cells were stimulated with gardiquimod (4 μg mL −1 ), LPS (1 μg mL −1 ), CpG (4 μg mL −1 ), cGAMP (4 μg mL −1 ), or Poly (I:C) (4 μg mL −1 ) for 24, 48, or 72 h. Whole-cell extracts were analysed by immunoblotting. f TMEM173 mRNA was assessed by qPCR in PMDC05 stimulated with indicated agonists for 48 h. Data are the means ± s.e.m. of one experiment performed in triplicate. g PMDC05 cells were pre-treated with the Nrf2 inhibitor ML385 (20 µM) before stimulation with LPS (1 μg mL −1 ) or gardiquimod (4 μg mL −1 ) for 72 h. Cells were then lysed and lysates were analysed by western blotting. h PMDC05 cells were pre-stimulated with gardiquimod (4 μg mL −1 ) or LPS (1 μg mL −1 ) for 72 h before challenge with cGAMP (4 μg mL −1 ) for 24 h. Type I IFN release was assessed using a HEK-Blue assay. Data are the means ± s.e.m. of one representative experiment performed in triplicate. i Graphical display of how 4-OI might possibly activate Nrf2. j HEK293T cells were treated with increasing doses of 4-OI (30–250 μM) for 18 h. ARE-promoter activity was assessed by luciferase assay. Data are means ± s.e.m. of two independent experiments in triplicate. k THP1 cells were treated with SFN (20 μM) or 4-OI (125 μM) for 48 h and mRNA levels were determined by qPCR. l THP1 cells were pre-treated with increasing does of 4-OI (62.5–125 μM) for 72 h and challenged with cGAMP (4 μg mL −1 ). Whole-cell lysates were then blotted as indicated. Data are from one representative experiment that has been repeated twice. m – n THP1 cells were pre-treated with 4-OI (125 μM) for 72 h before challenge of 24 h with cGAMP (4 μg mL −1 ). Supernatants were assessed for type I IFN by HEK-Blue cell assay ( m ) and whole-cell lysates by immunoblotting ( n ). o , p HaCat and A549 cells were treated with Nrf2 siRNA for 72 h and for 48 h, respectively, before treatment with 4-OI (125 μM) for 48 h. Whole-cell lysates were used for immunoblotting. q – s mRNA levels ( q , r ) and protein levels ( s ) were assessed by qPCR and immunoblotting in hMDMs silenced for Nrf2 by siRNA. Data are from two donors. Unpaired two-tailed Student’s t -test was used to determine significance

Article Snippet: ML385 was purchased from Axon MedChem and dissolved in DMSO.

Techniques: Liquid Chromatography with Mass Spectroscopy, Control, Western Blot, Activity Assay, Luciferase, Two Tailed Test